A 32-year-old man from rural Madhya Pradesh presents with a 3-month history of productive cough, fever, and night sweats. Chest X-ray shows cavitary lesions in the right upper lobe. Sputum smear microscopy is positive for acid-fast bacilli (AFB). He is started on standard first-line anti-TB therapy. After 2 months of treatment, repeat sputum smear remains positive despite good adherence. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Assessment of Treatment Failure **Key Point:** Failure to achieve sputum conversion by 2 months of standard first-line therapy (RIPE: Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) indicates treatment failure and raises strong suspicion for drug-resistant TB (DR-TB). ### Diagnostic Criteria for Treatment Failure | Timepoint | Criterion | Action | |-----------|-----------|--------| | 2 months | Sputum still positive (AFB+) | Treatment failure; suspect DR-TB | | 5 months | Sputum still positive (AFB+) | Definite treatment failure | | Any time | Reversion after initial conversion | Treatment failure | **High-Yield:** Per WHO and Indian TB guidelines (NTEP), persistent sputum positivity at 2 months of standard therapy is treatment failure until proven otherwise. ### Management Algorithm ```mermaid flowchart TD A["AFB+ TB on RIPE x 2 months"]:::outcome --> B{"Sputum still positive?"}:::decision B -->|Yes| C["Treatment Failure"]:::urgent C --> D["Send sputum for DST"]:::action D --> E["Initiate 2nd-line regimen"]:::action E --> F["Fluoroquinolone + Injectable + Bedaquiline"]:::action F --> G["Confirm resistance pattern"]:::outcome B -->|No| H["Continue standard therapy"]:::action ``` ### Why Switch to Second-Line Therapy? 1. **Drug resistance is highly likely** — persistent AFB positivity at 2 months despite adherence strongly suggests MDR-TB (resistance to INH and RIF). 2. **DST is mandatory** — to identify the resistance pattern and guide second-line regimen selection. 3. **Delay worsens outcomes** — continuing first-line drugs in DR-TB increases mortality and transmission risk. 4. **Standard second-line regimen** includes a fluoroquinolone (levofloxacin), an injectable (amikacin or streptomycin), and a newer agent (bedaquiline or linezolid). **Clinical Pearl:** Adherence has been confirmed in this patient, so non-adherence is not the cause of failure. Poor absorption, drug interactions, or malabsorption are less likely given the clinical context. **Warning:** Do NOT continue first-line therapy alone or add a single fluoroquinolone without DST — this risks further resistance amplification and treatment failure. [cite:Harrison 21e Ch 165]